drugset / Trial / NCT04485559
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
Phase 1
Recruiting
50 enrolled
University of California, San Francisco
Novartis Pharmaceuticals · collabPediatric Brain Tumor Foundation · collabThe Lilabean Foundation for Pediatric Brain Cancer Research · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase I trial studies the side effects and best dose of trametinib and everolimus in treating pediatric and young adult patients with gliomas that have come back (recurrent). Trametinib acts by targeting a protein in cells called MEK and disrupting tumor growth. Everolimus is a drug that may block another pathway in tumor cells that can help tumors grow. Giving trametinib and everolimus may work better to treat low and high grade gliomas compared to trametinib or everolimus alone.
Timeline
- Start
- 2020-12-09
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | — | Oral |
| Subject | Trametinib | Small molecule | — | Oral |